Clinicopathological significance of expression level of tumor-infiltrating lymphocytes in patients with HER2 positive breast cancer

doi:10.3760/cma.j.issn.1007-1245.2023.22.021

Abstract

Abstract:

Objective　To investigate the relationship between the expression of tumor-infiltrating lymphocytes (TILs) and clinicopathological characteristics, and the effect of TILs on prognosis in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. Methods　A total of 94 female patients with HER2 positive breast cancer treated at Tengzhou Central People's Hospital from October 2016 to October 2018 were collected, with a median age of 51 years (32-73 years). Among them, 49 patients took trastuzumab and chemotherapy, and 45 chemotherapy. The degree of TILs in the tumor area of each patient's HE section was evaluated. χ² test was used to analyze the category data. The Kaplan Meier survival curve and Cox proportional hazard regression model were used to analyze the prognostic factors. The relationship between the degree of TILs and the clinicopathological characteristics and the effect of TILs on the patients' recurrence free survival (RFS) were analyzed. Results　Among the 94 patients, 61 had low infiltration, and 33 high infiltration. There were no significant correlations between the degree of TILs and clinical pathological parameters (all P>0.05). In the targeted therapy group, 32 cases had low infiltration, and 17 cases high infiltration. The RFS of the patients with high TILs was longer than that of the patients with with low TILs (P=0.036); TNM stage and the degree of TILs were independent factors for the patients' prognosis (P=0.003 and 0.029). In the general chemotherapy group, 29 cases had low infiltration, and 16 cases high infiltration. The RFS of the patients with high TILs was longer than that of the patients with with low TILs (P=0.049); TNM stage and TILs were independent factors related to the patients' prognosis (P=0.001 and 0.028). Conclusions　TILs can be used as tumor markers in predicting the prognosis and therapeutic effect of patients with HER2 positive breast cancer, and may become new therapeutic targets for tumors.

Key words:

Breast cancer, Human epidermal growth factor receptor 2, Tumor-infiltrating lymphocytes, Prognosis

摘要：

目的　探讨人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）阳性型乳腺癌患者肿瘤浸润淋巴细胞（tumor infiltrating lymphocytes，TILs）表达与临床病理特征的相关性及与患者预后的关系。方法　收集滕州市中心人民医院2016年10月至2018年10月期间收治的HER2阳性型乳腺癌患者，共94例，均为女性，中位年龄51岁（32～73岁）。其中，49例患者接受曲妥珠单抗靶向治疗和化疗，45例患者仅接受化疗；评估每位患者HE切片肿瘤区域内TILs浸润程度，使用χ²检验对分类资料进行统计分析，使用Kaplan-Meier生存曲线和Cox回归法行单因素和多因素分析，分析TILs浸润程度与患者临床病理特征的关系和对患者无复发生存期（recurrence-free survival，RFS）的影响。结果　94例HER2阳性型乳腺癌患者，61例呈轻度浸润，33例呈重度浸润。TILs浸润程度与各临床病理参数均无明显相关性（均P>0.05）。靶向治疗组：32例呈轻度浸润，17例呈重度浸润。TILs重度浸润患者RFS长于TILs轻度浸润者（P=0.036）；TNM分期和TILs浸润程度均是HER2阳性型乳腺癌患者预后的独立因素（P=0.003、P=0.029）。普通化疗组：29例呈轻度浸润，16例呈重度浸润。TILs重度浸润者的RFS长于TILs轻度浸润者（P=0.049）；TNM分期和TILs浸润程度均是患者预后相关的独立因素（P=0.001、P=0.028）。结论　TILs可作为HER2阳性型乳腺癌预测预后和治疗效果的肿瘤标志物，并有可能成为肿瘤新的治疗靶点。

关键词:

乳腺癌, 人表皮生长因子受体2, 肿瘤浸润淋巴细胞, 预后

Man Qirong, Zhao Tiantian, Duan Chao, Li Ling.

Clinicopathological significance of expression level of tumor-infiltrating lymphocytes in patients with HER2 positive breast cancer [J]. International Medicine and Health Guidance News, 2023, 29(22): 3231-3235.

满其荣赵甜甜段超李苓.

HER2阳性型乳腺癌肿瘤间质淋巴细胞浸润程度表达的临床病理意义 [J]. 国际医药卫生导报, 2023, 29(22): 3231-3235.

References

[1] Krasniqi E, Barchiesi G, Pizzuti L, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives[J]. J Hematol Oncol, 2019,12(1):111. DOI: 10.1186/s13045-019-0798-2.
[2] Tang Y, Qiao G, Xu E, et al. Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer[J]. Onco Targets Ther, 2017,10:4527-4534. DOI: 10.2147/OTT.S142149.
[3] 吉芃,龚悦,狄根红.肿瘤浸润淋巴细胞在三阴性乳腺癌和HER2阳性乳腺癌中作用的最新研究进展[J].中国癌症杂志,2018,28(12):928-934.DOI:10.19401/j.cnki.1007- 3639. 2018.12.009.
[4] Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review[J]. JAMA Oncol, 2016,2(10):1354-1360. DOI: 10.1001/jamaoncol. 2016.1061.
[5] Piccart MJ, Hilbers FS, Bliss JM, et al. Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors[J]. J Clin Oncol, 2020,38(34):4120-4129. DOI: 10.1200/JCO.20.01382.
[6] Griguolo G, Pascual T, Dieci MV, et al. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer[J]. J Immunother Cancer, 2019 ,7(1):90. DOI: 10.1186/s40425-019-0548-6.
[7] Pusztai L, Karn T, Safonov A, et al. New strategies in breast cancer: immunotherapy[J]. Clin Cancer Res, 2016,22(9):2105-2110. DOI: 10.1158/1078-0432.CCR-15-1315.
[8] Miyoshi Y, Shien T, Ogiya A, et al. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer[J]. Oncol Lett, 2019,17(2):2177-2186. DOI: 10.3892/ol.2018.9853.
[9] Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers[J]. J Clin Oncol, 2019,37(7):559-569. DOI: 10.1200/JCO. 18.01010.
[10] 陈翱翔,余岳,孟然,等.肿瘤浸润淋巴细胞比例对乳腺癌新辅助化疗疗效的预测作用[J].中国肿瘤临床,2017,44(23):1184-1188.DOI:10.3969/j.issn.1000-8179.2017.23.994.
[11] 侯欣喜,李纳,耿文静,等.肿瘤浸润淋巴细胞在不同分子亚型乳腺癌中的意义及其临床病理学特征关系[J].诊断病理学杂志,2022,29(10):944-947.DOI:10.3969/j.issn. 1007-8096.2022.10.014.
[12] Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014[J]. Ann Oncol, 2015,26(2):259-271. DOI: 10.1093/annonc/mdu450.
[13] 杨月,张会芳,陈妙玲,等.富于淋巴细胞型乳腺癌中PD-L1和CD8+TILs的表达及临床意义[J].国际医药卫生导报,2022,28(23):3264-3269.DOI:10.3760/cma.j.issn. 1007-1245.2022.23.003.
[14] Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial[J]. Ann Oncol, 2014,25(8):1544-1550. DOI: 10.1093/annonc/mdu112.
[15] Gelber RD, Wang XV, Cole BF, et al. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a subpopulation treatment effect pattern plot (STEPP) analysis of the APHINITY (BIG 4-11) trial[J]. Eur J Cancer, 2022,166:219-228. DOI: 10.1016/j.ejca.2022.01.031.
[16] Perez EA, Ballman KV, Tenner KS, et al. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer[J]. JAMA Oncol, 2016,2(1):56-64. DOI: 10.1001/jamaoncol. 2015.3239.
[17] Kim RS, Song N, Gavin PG, et al. Stromal tumor-infiltrating lymphocytes in NRG oncology/NSABP B-31 adjuvant trial for early-stage HER2-positive breast cancer[J]. J Natl Cancer Inst, 2019,111(8):867-871. DOI: 10.1093/jnci/djz032.
[18] Dieci MV, Conte P, Bisagni G, et al. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer[J]. Ann Oncol, 2019,30(3):418-423. DOI: 10.1093/annonc/mdz007.
[19] Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial[J]. Lancet Oncol, 2019,20(3):371-382. DOI: 10.1016/S1470-2045(18)30812-X.
[20] Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol, 2020,21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4.